QUIGLEY ANNOUNCES POSITIVE IN-VITRO STUDY RESULTS FOR QR440

The Quigley Corporation, the leading developer and marketer of diversified health products, anounced that its whollyowned Quigley Pharma (Ethical Pharmaceuticals) subsidiary has obtained results from its continued preclinical research on QR440 -- a botanical broad-spectrum anti-inflammatory compound -- which show that QR440 may have disease-modifying potential.

In-vitro studies conducted at MD Biosciences supports the conclusion of previous animal study findings showing that QR440 can inhibit inflammatory cell recruitment and delayed type hypersensitivity (DTH). The current study suggests that the mechanism of action effecting cell recruitment and DTH is in fact the inhibition of a broad range of cytokine's including IL-2, IL-5, IL-12. In particular, these recent studies demonstrate that the compound inhibits IFNy and TNFa at 24 and 48 hours at low doses. The inhibition of TNFa is especially relevant in determining disease-modifying activity.